COVID And Medicare: Pricing Restraints Needed For Part B Vaccines, MedPAC Panelists Say
Executive Summary
GSK’s blockbuster Shingrix and other Part D vaccines would be switched to Part B under proposal being developed by influential advisory commission. Lack of pricing controls in Part B is generating concerns among panelists, though, as MedPAC aims to finalize its recommendations on revising Medicare reimbursement for vaccines by next spring.
You may also be interested in...
Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula
Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.
Medicare Permits Separate Vaccine Billing For Product, Administration
CMS will allow Part D vaccine administration to be billed and reimbursed separately from product costs in 2008, the agency states in guidance to Medicare drug plan sponsors issued May 14
Part D Vaccine Administration Payment Conundrum Addressed In Tax Bill
Physician administration of Part D vaccines will be covered under Medicare Part B during 2007 and under Part D in 2008 and thereafter, under broad tax and health care legislation (HR 6111) signed into law by President George Bush Dec. 20